Cargando…
Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis
The sofosbuvir-velpatasvir single-tablet regimen (Epclusa) is a newly FDA-approved inhibitor of hepatitis C virus (HCV). This meta-analysis aimed to investigate the safety and efficacy of velpatasvir-sofosbuvir in the treatment of chronic HCV infection. METHODS: A comprehensive literature search of...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592351/ https://www.ncbi.nlm.nih.gov/pubmed/36281168 http://dx.doi.org/10.1097/MD.0000000000031183 |
_version_ | 1784814905939984384 |
---|---|
author | Ren, Xiao-Dan Fu, Xue He, Yuan-Qun Li, Chun-Yan Guo, Meng Qiao, Min |
author_facet | Ren, Xiao-Dan Fu, Xue He, Yuan-Qun Li, Chun-Yan Guo, Meng Qiao, Min |
author_sort | Ren, Xiao-Dan |
collection | PubMed |
description | The sofosbuvir-velpatasvir single-tablet regimen (Epclusa) is a newly FDA-approved inhibitor of hepatitis C virus (HCV). This meta-analysis aimed to investigate the safety and efficacy of velpatasvir-sofosbuvir in the treatment of chronic HCV infection. METHODS: A comprehensive literature search of PubMed, Cochrane CENTRAL, EMBASE and Web of Science was conducted. Data from eligible studies were pooled in a fixed-effect meta-analysis model, using Open-Meta and RevMan software’s. RESULTS: Pooled data showed that velpatasvir-sofosbuvir achieved sustained virological response (SVR12) rates of 94.2% (95% CI 90.7–97.7%, P < .001) in 1277 patients. The addition of ribavirin did not significantly increase the SVR12 (RR = 1.03, 95%CI [0.95, 1.11]) in HCV genotype-1 patients and the SVR12 (RR = 1.09, 95%CI [0.86, 1.38]) in HCV genotype-2 patients. However, adding ribavirin significantly increased SVR12 (RR = 1.13, 95% CI [1.04, 1.23]) in genotype-3 patients. CONCLUSION: In conclusion, the 12-week regimen of sofosbuvir-velpatasvir was highly effective in HCV patients. Except for genotype-3, adding ribavirin was not associated with significant improvements in SVR12 rates. |
format | Online Article Text |
id | pubmed-9592351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95923512022-10-25 Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis Ren, Xiao-Dan Fu, Xue He, Yuan-Qun Li, Chun-Yan Guo, Meng Qiao, Min Medicine (Baltimore) 6600 The sofosbuvir-velpatasvir single-tablet regimen (Epclusa) is a newly FDA-approved inhibitor of hepatitis C virus (HCV). This meta-analysis aimed to investigate the safety and efficacy of velpatasvir-sofosbuvir in the treatment of chronic HCV infection. METHODS: A comprehensive literature search of PubMed, Cochrane CENTRAL, EMBASE and Web of Science was conducted. Data from eligible studies were pooled in a fixed-effect meta-analysis model, using Open-Meta and RevMan software’s. RESULTS: Pooled data showed that velpatasvir-sofosbuvir achieved sustained virological response (SVR12) rates of 94.2% (95% CI 90.7–97.7%, P < .001) in 1277 patients. The addition of ribavirin did not significantly increase the SVR12 (RR = 1.03, 95%CI [0.95, 1.11]) in HCV genotype-1 patients and the SVR12 (RR = 1.09, 95%CI [0.86, 1.38]) in HCV genotype-2 patients. However, adding ribavirin significantly increased SVR12 (RR = 1.13, 95% CI [1.04, 1.23]) in genotype-3 patients. CONCLUSION: In conclusion, the 12-week regimen of sofosbuvir-velpatasvir was highly effective in HCV patients. Except for genotype-3, adding ribavirin was not associated with significant improvements in SVR12 rates. Lippincott Williams & Wilkins 2022-10-21 /pmc/articles/PMC9592351/ /pubmed/36281168 http://dx.doi.org/10.1097/MD.0000000000031183 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 6600 Ren, Xiao-Dan Fu, Xue He, Yuan-Qun Li, Chun-Yan Guo, Meng Qiao, Min Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis |
title | Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis |
title_full | Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis |
title_fullStr | Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis |
title_full_unstemmed | Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis |
title_short | Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis |
title_sort | safety and efficacy of sofosbuvir-velpatasvir: a meta-analysis |
topic | 6600 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592351/ https://www.ncbi.nlm.nih.gov/pubmed/36281168 http://dx.doi.org/10.1097/MD.0000000000031183 |
work_keys_str_mv | AT renxiaodan safetyandefficacyofsofosbuvirvelpatasvirametaanalysis AT fuxue safetyandefficacyofsofosbuvirvelpatasvirametaanalysis AT heyuanqun safetyandefficacyofsofosbuvirvelpatasvirametaanalysis AT lichunyan safetyandefficacyofsofosbuvirvelpatasvirametaanalysis AT guomeng safetyandefficacyofsofosbuvirvelpatasvirametaanalysis AT qiaomin safetyandefficacyofsofosbuvirvelpatasvirametaanalysis |